Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
3.850
+0.350 (10.00%)
At close: Dec 5, 2025, 4:00 PM EST
3.999
+0.149 (3.88%)
After-hours: Dec 5, 2025, 7:58 PM EST
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
139.53M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GANX News
- 16 days ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - GlobeNewsWire
- 24 days ago - Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients - Seeking Alpha
- 5 weeks ago - Gain Therapeutics to Present at Neuroscience 2025 - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics to Attend the 2025 Maxim Growth Summit - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 - GlobeNewsWire